1,354,693 research outputs found
Decorazioni d’interni. Interior Decoration.
No full textIl contributo a cura di S. Paris recensisce il volume Interior/Design, Action on surfaces. Softness pubblicato nel 2013 a cura dell'autore e di R. Pagliarulo, evidenzia il ruolo della ricerca sul design delle superfici a livello internazionale. Se ne individua l'originalità e la sua dimensione scientifica nel declinare il ruolo delle superfici tra tettonica, interni e design
Material Inter-actions vs Sense Trans-action. Grit Surfaces
No full textThis paper examines the topic of the surfaces applied to interiors. It represents a new step in cladding research that broadens the investigation’s hori- zons from soft materials (Pagliarulo & Carullo, 2013, 2018; Pagliarulo, 2017) to rigid materials. This study opportunity is provided by the furniture design research conducted as part of the degree thesis (The paper collects part of the results carried out in the context of the degree thesis entitled: “GE | WAND. Ri | vestimenti di graniglia in terra di Puglia” [GE | WAND. Grit re | Claddings in Apulia]. Relatore: prof. R. Pagliarulo. Studenti: G. Addati, C. Colluto, A. Colonnato, F. Gallone, D. Gentile, M. Losito, A. Marotta, M. Merra, G. Monopoli, M. Morelli, N. Paradiso, G. Pastore, G. Valenza, A.M. Vitucci.), for the Industrial Design degree program at the Polytechnic of Bari, in collaboration with a company ( The company involved in the activity of the degree laboratory is the “Attivissimo”, active since 1950 in the production of grit, pastina and cementine.) that produces cement paste cov- ering in Apulia. Knowledge of both the traditional grit decoration patterns and of the production techniques formed the basis of a process of minute variations in the relationships between the materials. The cement mixture varies in size, shape, colour, and type of aggregates depending on the variational gradients. By enhancing the composition’s register, they also enhance the covering’s percep- tional sensory qualities. By varying the materiality of the composition, the surface rises from a two-dimensional plane of the composition to become an expressive text. The latter concerns mechanisms of perception and sensation, which intercept the most current design issues of interior coverings
Prognostic role of chromogranin A expression for docetaxel response in hormone-refractory metastatic prostate cancer
No full textBackground: The neuroendocrine (NE) cells in prostate cancer are indistinguishable from non-NE cancer cells morphologically and are usually detected by immunohistochemical study for NE markers. We analyzed the expression of Chromogranin A (Chr A) in malignant prostate tissue as prognostic factor for docetaxel response in metastatic HRPC. Methods: From January 2003 to December 2006, 40 patients with metastatic HRPC received a median of 12 cycles (range 2–18) of Docetaxel 75 mg/mq every 21 days and 5 mg of prednisone twice daily as initial therapy. Tissue blocks from primary prostate cancer tissues were obtained and immunostaining for Chr A was performed. The median age was 70 years (range 46–82); median baseline PSA: 310 ng/ml (range 0.15–700); median ECOG Performance Status: 1 (range 0- 2). PSA level was measured every 4 weeks and the treatment was considered effective if a rate of PSA-decline > 50% from baseline was found. TTP was the preliminary end point. Results: Response to Docetaxel was assessed at every 3 cycles of treatment. The Chr A expression was found in 19/40 patients with Gleason = 7, PSA < 20, bone and soft tissue metastasis; 10 of them showed PR (decrease in PSA < 50%), 4 SD and TTP was 9.2 months. Moreover they received second line chemotherapy without significant efficacy. 5/19 patients with Chr A expression showed PD, the PSA level was not correlated with clinical outcome, TTP was 5 months and were chemoresistant to different line treatment. Besides, Chr A was not detected in 21/40 patients with Gleason = 7, PSA > 20 and bone metastasis; 10 of them showed CR (PSA normalized) and 11 PR, TTP was 20 months. Conclusions: NE differentiation do not constituite a different histopathological category of prostate cancer but the NE phenotype can be correlated with poorly differentiated adenocarcinoma. NE differentiation can be considered a factor that influences prognosis and treatment in advanced prostate cancer; cases with Chr A expression did not benefit from Docetaxel and had poor prognosis. These preliminary data indicate that initial therapeutic approach should be different according to Chr A expression
Correlation between human epidermal growth factor receptor 2 (HER2) status and central nervous system (CNS) involvement in metastatic castration-resistant prostate cancer (mCRPC).
No full text 210 Background: The incidence of CNS metastasesin prostate cancer is very low. Recent data suggest that HER-2/neu is involved in progression of prostate cancer. Docetaxel-based chemotherapy has provided a survival advantage for mCRPC. The purpose of this retrospective study was to evaluate the relation between HER-2 status and risk of CNS metastases in pts with mCRPC treated with docetaxel. Methods: From 2003 to 2010, 130 pts with mCRPC were treated with 3wk docetaxel 75 mg/mq. 72/130 pts were retreated with the same regimen on disease progression. 50 out of these 72 pts received second docetaxel retreatment. All pts had bone metastases. Pts underwent total body CT scan before starting docetaxel chemotherapy and every 6 months during treatment. The median age was 66 (41–88), median baseline PSA: 110 ng/ml (range 5–1100), median ECOG Performance Status: 1 (range 0–2). The data on 130 pts, who underwent diagnostic biopsy or potentially curative resection , were reviewed. Tissue blocks from primary prostate cancer tissues were obtained. Grade 3 of the HER-2 by IHC staining was defined as a positive result or gene amplification by FISH. 10 out of these 50 pts receiving second docetaxel retreatment were diagnosed with CNS metastases. Results: CNS metastases were observed in HER-2 positive pts. 6/10 pts presented parenchymal metastases: 4 pts were asymptomatic, 3 pts underwent metastasectomy and all of them received palliative whole-brain RT. 4/10 pts presented leptomeningeal metastases with neurological symptoms and 2 of them received palliative whole-brain RT. The median time from prostate cancer diagnosis to the date of diagnosis of CNS metastases was 6 years (1–8). The median time from first cycle of docetaxel to the date of diagnosis of CNS metastases was 3 years (1.5–4). Conclusions: These preliminary data demonstrated that HER-2 expression confers an increased risk of CNS metastases in mCRPC and constitutes a therapeutic challenge. The apparent increase of CNS presentation may be related to the effectiveness of systemic therapy. These informations support the further evaluation of neurological symptoms in long-term docetaxel treated pts. </jats:p
DETECTION AND CLINICAL SIGNIFICANCE OF OCCULT LYMPH NODE METASTASES AND CIRCULATING CANCER CELLS IN PATIENTS WITH INVASIVE BLADDER CANCER
No full text
Contrast-enhanced multislice pneumo-CT-cystography in the evaluation of urinary bladder neoplasms
No full text
- …
